Respiratory Disorders Resource Center

Click on the subcategory below to find drug monographs for that particular area.

Persistent Cough Could Be Pertussis

20% of school-aged children with persistent cough have evidence of pertussis, even among those who are fully vaccinated.

Whooping Cough Epidemic in CA

More than 3,400 new cases of pertussis were reported in California between January 1 and June 10, making it an epidemic,

Barriers to Asthma Care

Cost-related barriers to care for children with asthma are concentrated in low-income families with higher cost-sharing levels.

Lung Cancer Trends Vary for Women

The rate of lung cancer mortality in young women is stable or declining in most populations, while increasing for older women.

Certain Foods Benefit COPD Patients

Certain foods, including grapefruit, have been linked to improved lung function and fewer symptoms in adults with COPD

Are Hot Sauce Fumes Harmful?

A Sriracha factory has been in the hot seat over complaints from residents regarding fumes emitted during the production of the hot sauce.

Asthma Treatments: Inhalations

Review this updated chart on inhalations for asthma treatment for quick information when you need it.

New Drug Product: Breo Ellipta

Long term maintenance treatment of airflow obstruction in COPD, including chronic bronchitis and/or emphysema.


Asthma Meds Could Stunt Children's Growth

For children with persistent asthma, use of inhaled corticosteroids (ICS) is associated with a significant reduction in linear growth velocity, with lower growth velocity for those receiving a higher dose of ICS.

In the ER, Faces Could ID Cardiopulmonary Disease

Decreased variability of facial expression may help identify patients with serious cardiopulmonary disease in the emergency care setting.

Sleep-Linked Death Risk Factors Vary With Infant Age

Risk factors for sleep-related infant deaths vary with infant age and parents should be warned about the dangers of these specific risk factors appropriate to their infant's age.

Nintedanib Granted Breakthrough Therapy for Idiopathic Pulmonary Fibrosis

The FDA has granted Breakthrough Therapy designation to Boehringer Ingelheim's nintedanib for the treatment of idiopathic pulmonary fibrosis (IPF).

Featured courses from mycme

Breathlessness - Red flag symptomsExternal web site

Breathlessness - Red flag symptoms

0.50 Credits

Pharmacology Workshop: New Drugs, Obesity, Arthritis (Pharmacology Credit)External web site

This activity provides in-depth guidance for the pharmacologic and nonpharmacologic treatment of arthritis, and management ...

CE 3.00 Credits

Sign Up for Free e-newsletters